Tübingen, Germany

Latifa Zekri-Metref

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 4.5

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2023-2025

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Latifa Zekri-Metref: Innovator in Antibody Development

Introduction

Latifa Zekri-Metref is a prominent inventor based in Tübingen, Germany. She has made significant contributions to the field of antibody development, particularly in the area of prostate-specific membrane antigen (PSMA) binding antibodies. With a total of 3 patents, her work has the potential to impact both pharmaceutical and diagnostic applications.

Latest Patents

Latifa's latest patents include a novel PSMA binding antibody termed 10B3. This invention provides pharmaceutical and diagnostic uses of the antibody 10B3. Notably, the PSMA antibody 10B3 does not cross-compete with the established PSMA binding antibody J591. Additionally, it exhibits a reduced induction of antigen shift compared to J591 and demonstrates unique reactivity with squamous cell carcinoma (SCC) cells of different origins.

Career Highlights

Throughout her career, Latifa has worked with esteemed institutions such as the Deutsches Krebsforschungszentrum and Eberhard Karls Universität Tübingen. Her research has focused on advancing the understanding and application of antibodies in medical science.

Collaborations

Latifa has collaborated with notable colleagues, including Helmut Salih and Fabian Vogt. These partnerships have contributed to her innovative research and development efforts.

Conclusion

Latifa Zekri-Metref is a trailblazer in the field of antibody research, with her inventions paving the way for advancements in cancer diagnostics and treatment. Her contributions are invaluable to the scientific community and hold promise for future medical applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…